CASANDRA MOYER: Open Payments
NPI 1891162384 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$348 in 11 payments from 6 companies in 2025. Trend: 2023 $382 · 2024 $179 · 2025 $348
Food & beverage: $348
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 2 | $159 |
| Janssen Pharmaceuticals, Inc | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| ABBVIE INC. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
Products named: INGREZZA, INVEGA SUSTENNA, REXULTI, COBENFY, VRAYLAR, CAPLYTA.
Industry payments across CA — which companies pay providers there.
